Stockreport

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Infl...

NanoViricides, Inc.  (NNVC) 
NASDAQ:AMEX Investor Relations: nanoviricides.com/investorinfo.html
PDF Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accesse [Read more]